Vanguard Group’s ProQR Therapeutics PRQR Stock Holding History

Vanguard Group’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-13,720	Closed	-$79K	–	4134
2019 Q3	$79K	Hold	13,720	–	–	﹤0.01%	4052
2019 Q2	$125K	Hold	13,720	–	–	﹤0.01%	4028
2019 Q1	$191K	Sell	13,720 -1,300	-9%	-$19.4K	﹤0.01%	3934
2018 Q4	$237K	Buy	+15,020	New	+$276K	﹤0.01%	3871

Other funds holding PRQR

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Vanguard Group's PRQR Position: Q4 2019 in Review

Vanguard Group sold out of ProQR Therapeutics (PRQR) in Q4 2019, closing a stake of 13,720 shares — an estimated $79K sold.

Vanguard Group first reported a position in PRQR in Q4 2018 and held it in 4 quarters. The position peaked at $237K in Q4 2018. 51 funds tracked by Wall St. Rank hold PRQR as of Q4 2019.

Vanguard Group reported no remaining ProQR Therapeutics position as of Q4 2019 after selling out during the quarter.
Vanguard Group sold 13,720 ProQR Therapeutics shares in Q4 2019, an estimated $79K.
Vanguard Group first reported a position in ProQR Therapeutics in Q4 2018 and held it in 4 quarters.
Vanguard Group's ProQR Therapeutics position peaked at $237K in Q4 2018.
51 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q4 2019.

Based on Vanguard Group's 13F filing for Q4 2019, filed 14 Feb 2020.